Home > PJ (current issue) > Letters | Search

PJ Online homeThe Pharmaceutical Journal
Vol 280 No 7485 p54
19 January 2008

This article
Reprint   Photocopy

PDF 70K, Acrobat Reader

Letters

• Industrial pharmacists (4)
• Community pharmacy
• Responsible pharmacist (2)
• Package design
• The profession (2)
• The Society (3)
• Registration (2)
• Statins
• Retirement (2)
• Onlooker
• Caption competition


Letters to the Editor

Statins

Many people do not take statins as described

From Mr J. Knowles, MRPharmS

It is important that a pharmacist takes the utmost care when publicly supporting an advertisement feature placed in The Pharmaceutical Journal (5/12 January 2008), particularly when that pharmacist is employed by the NHS to give prescribing advice.

The Journal insert advertising ezetimibe is a case in point. No mention is made of patient compliance. Those of us working in primary care often encounter patients whose cholesterol levels are not on target because they do not take their statin as prescribed.

There are many reasons for poor compliance, and primary care pharmacists are in a good position to explore these and find solutions. Similarly, community pharmacists can help with judicious use of medicines use reviews. I am disappointed that Omar Ali omitted this important issue in his article.

The advertisement feature uses a five-year-old survey published in the British Journal of Cardiology to support its claim that “35 per cent of patients with coronary heart disease in the UK are not reaching government cholesterol targets despite effective treatment therapies”.

There is no mention in the survey of the statin doses used except to say that the figure improved to 22 per cent after review of statin treatment. This hardly supports the advertisement feature’s claim.

Mr Ali also omitted to mention the fact that ezetimibe has no robust cardiovascular disease outcome data, in contrast to a number of statins. This should be taken into account when deciding which path to follow when a patient is not to target.

The National Institute for Clinical Excellence clearly explains the place of ezetimibe in treatment. I agree with Mr Ali that anyone who requires clarification should log on to the website or may wish to discuss the issue with a medicines management pharmacist. Contact with such pharmacists can be made by contacting local primary care trusts.

John Knowles
Locality Lead Pharmacist
Walsall Teaching Primary Care Trust

Send your letter to The Editor

Previous Topic (Registration)
Next Topic (Retirement)

Back to Top


©The Pharmaceutical Journal